1. Bourassa MG, Butnaru A, Lespérance J, Tardif JC. Symptomatic myocardial bridges: overview of ischemic mechanisms and current diagnostic and treatment strategies. J Am Coll Cardiol 2003;41:351–9. 2. Kramer JR, Kitazume H, Proudfit WL, Sones FM Jr. Clinical significance of isolated coronary bridges: benign and frequent condition involving the left anterior descending artery. Am Heart J 1982;10...

BACKGROUND The aim of this study was to investigate the clinical outcome 2 years after intracoronary administration of autologous progenitor cells in patients with acute myocardial infarction (AMI). METHODS AND RESULTS Using a double-blind, placebo-controlled, multicenter trial design, we randomized 204 patients with successfully reperfused AMI to receive intracoronary infusion of bone marrow...

BACKGROUND Profound reduction in antegrade epicardial coronary flow with concomitant ischemia is seen occasionally during percutaneous coronary intervention despite the absence of evident vessel dissection, obstruction, or distal vessel embolic cutoff. In a prior small series of cases, this "no-reflow" phenomenon appeared to be promptly reversed by the intra-coronary administration of verapamil...

AIMS To investigate the clinical outcome after intracoronary administration of autologous progenitor cells in patients with acute myocardial infarction (AMI). METHODS AND RESULTS Using a double-blind, placebo-controlled multicentre trial design, we randomized 204 patients with successfully reperfused AMI to receive intracoronary infusion of bone-marrow-derived progenitor cells (BMCs) or place...

THROMBOLYTIC THERAPY in patients with acute myocardial infarction has received renewed attention since intracoronary infusion of streptokinase has been introduced into clinical practice. Efficacy of intracoronary infusion of streptokinase. In-tracoronary infusion of streptokinase results in recana-lization of approximately 75% of completely obstructed infarct-related vessels" 2 (table 1). Modif...

AIMS Previous trials that investigated cell therapy as an adjunctive therapy after acute myocardial infarction (AMI) have shown conflicting results. We designed a randomized controlled trial to determine the effect of intracoronary infusion of mononuclear cells from bone marrow (BM) or peripheral blood in patients with AMI. METHODS AND RESULTS In a multicentre trial, 200 patients with large f...

AFTER THE INTRACORONARY application of metal stents initially proposed by U. Sigward, a very aggressive anti thrombotic treatment was used. During the last years, however, the anti thrombotic treatment has been completely reevaluated. Currently, the therapy with ticlopedine and aspirin reveals excellent results with little bleeding. The current indications of stent implantation are severe disse...

BACKGROUND Administration of abciximab during primary percutaneous coronary intervention is an effective adjunctive therapy in the treatment of patients with ST-segment elevation myocardial infarction. Recent small-scaled studies have suggested that intracoronary administration of abciximab during primary percutaneous coronary intervention is superior to conventional intravenous administration....

Clinically encouraging results can be obtained with an intravenous high dose short-time infusion of streptokinase in patients with evolving myocardial infarction. The feasibility and efficacy of the intracoronary and the systemic approach of streptokinase therapy in acute myocardial infarction are discussed in this report and include topics such as infarct artery recanalization success rate, co...

BACKGROUND Although granulocyte colony-stimulating factor (G-CSF) is known to prevent left ventricular (LV) remodeling after acute myocardial infarction (AMI), the best method of administration is unknown. METHODS AND RESULTS A rabbit ischemia/reperfusion model was created and G-CSF was administered into the coronary artery immediately after reperfusion. The LV size and contraction were deter...